Summary:
In patients with proliferative diabetic retinopathy and retinal detachment, adjunctive intravitreal dexamethasone implantation during vitrectomy with silicone oil tamponade significantly reduced the progression of preretinal proliferation, incidence of macular epiretinal membrane, and improved visual outcomes compared to vitrectomy and silicone oil tamponade alone, though it was associated with no notable adverse effects reported in the study.
| PICO | Description |
|---|---|
| Population | Patients diagnosed with proliferative diabetic retinopathy complicated by retinal detachment undergoing vitrectomy with silicone oil tamponade (N=30 patients, 34 eyes). |
| Intervention | Adjunctive intravitreal dexamethasone (Ozurdex) implantation administered after vitrectomy and prior to silicone oil tamponade. |
| Comparison | Standard treatment comprising vitrectomy and silicone oil tamponade without dexamethasone implantation. |
| Outcome | The dexamethasone group showed significantly lower progression of preretinal proliferation (23.5% vs. 88.2%, p=0.000), reduced area of preretinal membranes, lower incidence of macular epiretinal membrane (11.8% vs. 41.2%, p=0.024), improved mean BCVA at 12 months (0.61±0.70 vs. 1.02±1.00 logMAR, p=0.024), and reduced CRT at 1 and 6 months (p=0.008 and 0.024 respectively). |
Source: Yu Cao, et al. “Outcome of silicone oil tamponade combined dexamethasone implantation in patients with proliferative diabetic retinopathy and retinal detachment undergoing vitrectomy: a prospective randomized controlled clinical trial.” Read article here.
